Table 2.
Variable | Disease-specific survival |
Overall survival |
||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Cancer Subtype | ||||||
Adenosquamous carcinoma | 2.87 | 1.59, 4.76 | .0010 | 2.57 | 1.43, 4.26 | .0027 |
Adenocarcinoma | ref | ref | ||||
Age, y | ||||||
Each additional year | 1.01 | 1.00, 1.023 | .0030 | 1.02 | 1.01, 1.03 | <.0001 |
Gender | ||||||
Male | 1.26 | 0.94, 1.73 | .1221 | 1.30 | 0.97, 1.76 | 0.0751 |
Female | ref | ref | ||||
T stage | ||||||
T3-4 | 1.87 | 1.50, 2.35 | <.0001 | 1.80 | 1.46, 2.24 | <.0001 |
T1-2 | ref | ref | ||||
No. metastatic nodes | ||||||
Each additional node | 1.10 | 1.09, 1.13 | <.0001 | 1.10 | 1.08, 1.12 | <.0001 |
Tumor Grade | ||||||
4 | 1.30 | 1.08, 1.57 | .0066 | 1.30 | 1.08, 1.55 | 0.0052 |
1 to 3 | ref | ref | ||||
HER2 status | ||||||
Positive | 1.00 | 0.77, 1.28 | 1.00 | 0.96 | 0.74, 1.22 | 0.7205 |
Negative | ref | ref |
Abbreviations: CI, confidence interval; HR, hazard ratio; ref; reference.
HRs are adjusted for all variables shown. Values >1 denote a higher risk of adverse survival compared to the reference level.